Skip to main content
Sun Pharmaceutical Industries Ltd. logo

Sun Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · SUNPHARMA ISIN · INE044A01036 LEI · 335800KJ7GE29LB4SS73 BSE.NS Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2026-01-20 Regulatory Filings
Country IN India
Listing BSE.NS SUNPHARMA

About Sun Pharmaceutical Industries Ltd.

https://sunpharma.com/

Sun Pharmaceutical Industries Ltd. is a global leader in specialty generic pharmaceuticals, focused on developing, manufacturing, and marketing a comprehensive range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company’s extensive portfolio covers diverse therapeutic segments, including cardiology, psychiatry, neurology, gastroenterology, ophthalmology, dermatology, and orthopedics. It provides high-quality, affordable medicines across more than 100 markets worldwide, serving both chronic and acute care needs. A significant emphasis is placed on research and development to produce complex generics and innovative specialty products. The organization maintains a robust global manufacturing footprint, operating facilities that comply with stringent international regulatory standards. Its offerings encompass generics, branded generics, specialty medications, and over-the-counter products, aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-20 English
Record Date
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Sun Pharmaceutical Industries Limited regarding a scheduled Board Meeting to consider and approve unaudited financial results for the quarter and nine months ended 31 December 2025, and to consider the declaration of an interim dividend. It also includes information about the record date for the interim dividend and trading window closure. The document is short (2489 characters) and serves as a notification of upcoming board decisions and dividend declaration, not the actual financial report or dividend payment details. Therefore, it is best classified as a Capital/Financing Update (CAP) because it relates to dividend declaration and financial results approval, but does not contain the financial results themselves.
2026-01-20 English
Board Meeting — Financial Results/Dividend
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Sun Pharmaceutical Industries Limited regarding a scheduled Board Meeting to consider and approve unaudited financial results for the quarter and nine months ended 31 December 2025, and to consider the declaration of an interim dividend. It also includes information about the record date for the interim dividend and trading window closure. The document is short (2489 characters) and serves as a notification of upcoming financial results and dividend declaration, not the financial report itself. Therefore, it is an announcement related to dividend and financial results but does not contain the actual financial data or detailed report. This fits the category of Notice of Dividend Amount (DIV) because it announces the potential declaration of an interim dividend and related details. The mention of financial results approval is part of the board meeting agenda but the document does not contain the results themselves, so it is not an Interim/Quarterly Report (IR) or Earnings Release (ER).
2026-01-20 English
News Verification
Regulatory Filings Classification · 100% confidence The document is a letter from Sun Pharmaceutical Industries Limited addressed to the National Stock Exchange of India Limited. It is a response to a rumor verification request regarding a speculative news article about a potential acquisition. The letter clarifies that there is no material event requiring disclosure under the relevant listing regulations and mentions adherence to governance and disclosure standards. The document does not contain any financial data, report, or detailed announcement of a transaction but is rather a regulatory communication clarifying the absence of material information. It is short (1823 characters) and serves as a regulatory filing to address market rumors and compliance inquiries. Therefore, it fits best under Regulatory Filings (RNS).
2026-01-20 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release from Sun Pharmaceutical Industries Limited announcing the availability of a new drug, UNLOXCYT, for advanced cutaneous squamous cell carcinoma. It includes detailed product information, clinical trial results, safety information, and contact details. There is no financial data, regulatory filing, or report attached or referenced. The document is an announcement of a product availability and related information, not a financial report, management update, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The closest fitting category is a general regulatory announcement or compliance-related disclosure under SEBI regulations, but since it is primarily a press release about product availability and not a financial or governance report, the best classification is Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-01-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 100% confidence The document is a confirmation certificate submitted pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It confirms the dematerialisation of securities for the quarter ended 31 December 2025. The document is a compliance certificate from the Registrar & Share Transfer Agent to the company and stock exchanges. It does not contain financial statements, management discussion, or detailed report content. The document length is short (2965 characters) and is primarily a certification letter. According to the rules, such certification documents should be classified as Regulatory Filings (RNS).
2026-01-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.